Bruker Executive and Leadership Team

Frank Laukien, the Chairman, President & Chief Executive Officer at Bruker, directs the overarching corporate strategy and long-term vision for the organization. Laukien oversees the development of advanced scientific instruments, ensuring the company maintains a competitive edge in mass spectrometry and magnetic resonance technologies. By aligning research initiatives with industrial needs, the Chief Executive Officer drives growth across life sciences and materials research sectors. This leadership role involves constant engagement with the Board to optimize capital allocation and market expansion. Frank Laukien monitors global operational performance, ensuring that Bruker delivers high-quality analytical solutions to researchers and clinicians worldwide. Through rigorous focus on innovation and quality control, the Chairman, President & Chief Executive Officer secures the company's position as a leader in scientific technology. Laukien fosters a culture of excellence, pushing the boundaries of molecular spectroscopy and X-ray analysis to solve critical scientific problems.

Gerald Herman, the Chief Financial Officer at Bruker, manages the global financial health and fiscal strategy of the corporation. Herman oversees capital structure, financial reporting, and investor relations, ensuring transparency and stability for stakeholders. By analyzing market trends in analytical technologies, the Chief Financial Officer supports strategic investments in manufacturing and research infrastructure. This role requires close collaboration with executive leadership to maintain robust balance sheets while funding high-growth initiatives in healthcare and industrial applications. Gerald Herman directs the financial planning and analysis teams, providing the data necessary for informed decision-making across all business units. Through disciplined cost management and revenue optimization, the Chief Financial Officer strengthens the company's ability to scale operations internationally. Herman ensures that financial resources align with the long-term mission of advancing scientific discovery, ultimately protecting the economic interests of the organization while facilitating sustainable expansion in diverse global markets.

Aviad Gilad, the Chief Financial Officer, Bruker Technologies at Bruker, handles the financial operations specifically tied to the technology division. Gilad oversees the budgeting and resource allocation for the development of advanced microscopy and diagnostic systems. By monitoring the profitability of specific product lines, the Chief Financial Officer, Bruker Technologies ensures that technical innovation remains financially viable and aligned with corporate goals. This role involves managing the financial risks associated with complex manufacturing processes and supply chain logistics. Aviad Gilad works with engineering teams to optimize the cost-to-performance ratio of new analytical tools, directly impacting the market competitiveness of the technology portfolio. Through precise financial modeling and performance tracking, the Chief Financial Officer, Bruker Technologies supports the rapid deployment of new scientific instruments. Gilad maintains fiscal discipline while enabling the research and development necessary to keep the company at the forefront of materials research and industrial testing.

Bryce McEuen, the President, Bruker Biomedical Systems at Bruker, leads the operational and strategic direction of the biomedical systems division. McEuen oversees the design, manufacturing, and distribution of diagnostic systems used by clinicians and researchers to investigate biological processes. By driving product development cycles, the President, Bruker Biomedical Systems ensures that the company meets the evolving needs of the healthcare sector. This leadership role involves coordinating with global sales and support teams to expand the reach of diagnostic technologies into new clinical environments. Bryce McEuen manages the integration of advanced analytical capabilities into user-friendly systems, enhancing the efficiency of medical research. Through a focus on operational excellence and customer-centric innovation, the President, Bruker Biomedical Systems secures market share in the competitive life sciences landscape. McEuen directs the division toward achieving high-impact outcomes, ensuring that the technology provided by the company consistently improves quality control and diagnostic accuracy for customers worldwide.